We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
126
DELISTED
Zogenix, Inc.
ZGNX
$2.48M 0.11%
62,074
-62,074
-50% -$2.86M
SYNH
127
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$2.45M 0.11%
45,982
+16,955
+58% +$870K
RCKT icon
128
Rocket Pharmaceuticals
RCKT
$351M
$2.42M 0.11%
+207,555
New +$2.58M
APLS
129
DELISTED
Apellis Pharmaceuticals
APLS
$2.38M 0.1%
+98,784
New +$2.72M
ANAB icon
130
AnaptysBio
ANAB
$1.63B
$2.36M 0.1%
67,496
-7,302
-10% -$347K
ICPT
131
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.28M 0.1%
34,414
-19,443
-36% -$1.31M
HR
132
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.28M 0.1%
68,000
– –
TFX icon
133
Teleflex
TFX
$5.86B
$2.17M 0.09%
6,379
– –
HOLX
134
DELISTED
Hologic
HOLX
$2.16M 0.09%
42,701
– –
BCEL
135
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.05M 0.09%
167,245
-7,755
-4% -$118K
QTNT
136
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.02M 0.09%
+6,501
New +$2.51M
PHG icon
137
Philips
PHG
$25.8B
$1.97M 0.09%
53,720
-53,720
-50% -$1.98M
IBB icon
138
iShares Biotechnology ETF
IBB
$9.52B
$1.88M 0.08%
+18,914
New +$1.98M
HQY icon
139
HealthEquity
HQY
$8.44B
$1.82M 0.08%
31,810
– –
QURE icon
140
uniQure
QURE
$2.93B
$1.73M 0.08%
43,849
+24,098
+122% +$1.39M
ENDP
141
DELISTED
Endo International plc
ENDP
$1.71M 0.07%
531,570
– –
EVH icon
142
Evolent Health
EVH
$358M
$1.66M 0.07%
231,027
+56,757
+33% +$407K
DOC icon
143
Healthpeak Properties
DOC
$15.2B
$1.62M 0.07%
45,500
– –
RVTY icon
144
Revvity
RVTY
$12.7B
$1.62M 0.07%
+19,011
New +$1.66M
LKFT
145
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$1.4M 0.06%
9,141
-39,384
-81% -$6.45M
HR icon
146
Healthcare Realty
HR
$7.46B
$1.35M 0.06%
46,000
– –
RARX
147
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.32M 0.06%
55,829
+36,639
+191% +$1.09M
AERI
148
DELISTED
Aerie Pharmaceuticals
AERI
$1.28M 0.06%
66,688
– –
ARNA
149
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.28M 0.06%
28,002
– –
VRNA
150
DELISTED
Verona Pharma
VRNA
$1.26M 0.05%
275,000
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.